[Federal Register Volume 71, Number 222 (Friday, November 17, 2006)]
[Notices]
[Pages 66974-66975]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: E6-19446]


=======================================================================
-----------------------------------------------------------------------

DEPARTMENT OF JUSTICE

Drug Enforcement Administration


Importer of Controlled Substances; Notice of Application

    Pursuant to 21 U.S.C. 958(i), the Attorney General shall, prior to 
issuing a registration under this Section to a bulk manufacturer of a 
controlled substance in schedule I or II and prior to issuing a 
regulation under 21 U.S.C. 952(a) (2) (B) authorizing the importation 
of such a substance, provide manufacturers holding registrations for 
the bulk manufacture of the substance an opportunity for a hearing.
    Therefore, in accordance with 21 CFR 1301.34(a), this is notice 
that on September 14, 2006, Kenco VPI, Division of Kenco Group Inc., 
350 Corporate Place, Chattanooga, Tennessee 37419, made application by 
renewal to the Drug Enforcement Administration (DEA) to be registered 
as an importer of Nabilone (7379), a basic class of controlled 
substance listed in schedule II.
    The company plans to import the listed controlled substance for 
distribution to its customers.
    Any manufacturer who is presently, or is applying to be, registered 
with DEA to manufacture such basic class of controlled substance may 
file comments or objections to the issuance of the proposed 
registration and may, at the same time, file a written request for a 
hearing on such application pursuant to 21 CFR 1301.43 and in such form 
as prescribed by 21 CFR 1316.47.

[[Page 66975]]

    Any such written comments or objections being sent via regular mail 
should be addressed, in quintuplicate, to the Deputy Assistant 
Administrator, Office of Diversion Control, Drug Enforcement 
Administration, Washington, DC 20537, Attention: DEA Federal Register 
Representative/ODL; or any being sent via express mail should be sent 
to DEA Headquarters, Attention: DEA Federal Register Representative/
ODL, 2401 Jefferson-Davis Highway, Alexandria, Virginia 22301; and must 
be filed no later than December 18, 2006.
    This procedure is to be conducted simultaneously with and 
independent of the procedures described in 21 CFR 1301.34(b), (c), (d), 
(e) and (f). As noted in a previous notice published in the Federal 
Register on September 23, 1975, (40 FR 43745-46), all applicants for 
registration to import a basic class of any controlled substance listed 
in schedule I or II are, and will continue to be required to 
demonstrate to the Deputy Assistant Administrator, Office of Diversion 
Control, Drug Enforcement Administration, that the requirements for 
such registration pursuant to 21 U.S.C. 958(a), 21 U.S.C. 823(a), and 
21 CFR 1301.34(b), (c), (d), (e) and (f) are satisfied.

    Dated: November 8, 2006.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of Diversion Control, Drug 
Enforcement Administration.
[FR Doc. E6-19446 Filed 11-16-06; 8:45 am]
BILLING CODE 4410-09-P